Irinotecan plus carboplatin for patients with carcinoma of unknown primary site

Carcinoma of unknown primary site (CUP) is rarely encountered in clinical practice and optimal chemotherapy has not yet been established. This phase II study was conducted to evaluate the efficacy and toxicity of combined irinotecan+carboplatin therapy in chemotherapy-naive patients with CUP. Irinot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonemori, K, Ando, M, Yunokawa, M, Hirata, T, Kouno, T, Shimizu, C, Tamura, K, Katsumata, N, Hirakawa, A, Matsumoto, K, Yamanaka, Y, Arioka, H, Fujiwara, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634680/
https://www.ncbi.nlm.nih.gov/pubmed/19088717
http://dx.doi.org/10.1038/sj.bjc.6604829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634680/
https://www.ncbi.nlm.nih.gov/pubmed/19088717
http://dx.doi.org/10.1038/sj.bjc.6604829

Ejemplares similares